zurück

Burosumab (new indication, 50 M € limit exceeded: FGF23-related hypophosphatemia in tumor-induced osteomalacia)

 

Subject:

  • Active Sustance: Burosumab
  • Name: Crysvita®
  • Therapeutic area: Hypophosphatemia
  • Pharmaceutical company: Kyowa Kirin GmbH

 

Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023

 

Comparative therapy:

  • Phosphate substitution